troglitazone has been researched along with Hematologic Malignancies in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Turturro, F | 1 |
Lawson, M | 1 |
Friday, E | 1 |
Welbourne, T | 1 |
1 other study available for troglitazone and Hematologic Malignancies
Article | Year |
---|---|
Targeting the Na(+)/H(+) exchanger: an old concept with new perspectives in the treatment of hematological malignancies.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromans; Hematologic Neoplasms; Humans | 2007 |